Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Xcel Energy Inc (XEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Xcel Energy Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $224 (market cap $29.60B), while Xcel Energy Inc trades at $77.47 (market cap $48.51B). The key difference: Xcel Energy Inc is the larger of the two by market cap, and Xcel Energy Inc pays a 3.05% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | XEL | |
|---|---|---|
Market Cap | $29.60B | $48.51B |
Sector | Health | Utilities |
52-Week High | $491.22 | $83.91 |
52-Week Low | $205.48 | $71.75 |
Enterprise Value | $27.56B | $86.82B |
Dividend Yield | — | 3.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
Xcel Energy (XEL) trades at $78.33, up 1.9% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong Q2 2026 earnings of $0.93 per share, beating estimates, driven by infrastructure investment recovery. Revenue for 2025 was $14.67 billion with a net income margin of 15.28%. Analysts maintain a consensus buy rating with a $93.80 price target, highlighting growth from a $60 billion capital plan through 2030.
The outlook for XEL is positive due to projected EPS growth and rising electricity demand, but risks include regulatory pushback on rate increases and high capital expenditure. The stock offers stability with a dividend yield, yet valuation remains near historical highs, requiring careful monitoring of execution against its expansive investment strategy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Xcel Energy Inc
Xcel Energy manages utilities serving 3.7 million electric customers and 2.1 million natural gas customers in eight states. Its utilities are Northern States Power, which serves customers in Minnesota, North Dakota, South Dakota, Wisconsin, and Michigan
Read more on XEL →
